CClinicalTrials.gg
Not yet recruitingNCT06549049Updated Sep 29, 2026

A Transdiagnostic Sleep Health Intervention for Veterans With PTSD

An interventional study of TranS-C for PTSD and Sleep Psychoeducation Control in Stress Disorders, Post-Traumatic and Sleep Initiation and Maintenance Disorders, sponsored by VA Office of Research and Development. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-29.

Sponsored by VA Office of Research and Development · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
182
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Sleep disturbance is a major problem in Veterans with posttraumatic stress disorder (PTSD). This study will test a version of a sleep treatment that's been shown to be effective in the general population, with some changes to tailor it to the needs of Veterans with PTSD and sleep disturbance.

Read the detailed description

Sleep disturbance in military Veterans with PTSD is a complex condition, typically characterized by insomnia and nightmares, and frequently accompanied by comorbid obstructive sleep apnea. Each of these problems are shown to influence the others, contributing to a complex sleep disturbance with profound impacts on daytime functioning and quality of life. A vicious cycle in which nighttime disturbances impact daytime functioning, and vice versa, often ensues. Addressing sleep disturbance in Veterans with PTSD therefore requires a multipronged approach that is tailored to each Veterans' constellation of symptoms and each Veterans' goals for sleep health. The Transdiagnostic sleep and circadian intervention (TranS-C), developed by sleep researchers Allison Harvey, Ph.D. and Daniel Buysse, M.D., involves a patient-centered, module-based, flexibly structured approach that tackles numerous sleep disturbances using evidence-based strategies with the overall goal of improving sleep and improving sleep-related impairments in daytime functioning. It is thus well-suited for tackling sleep disturbances and the associated impairments in social, occupational and overall functioning in Veterans with PTSD. The proposed study is a randomized, controlled clinical trial examining the effectiveness of a modified TranS-C intervention for Veterans with PTSD. The modified approach, referred to as TranS-C for PTSD (TSC-PTSD) elevates the importance of nightmare-focused, apnea-focused, and insomnia-focused modules relative to the standard intervention, incorporates an evidence-based relaxation module, and modifies the nightmare and apnea modules based on strategies used for Veterans in the VA healthcare system. The study will administer TSC-PTSD remotely to Veterans in their homes using a VA-approved video-conferencing platform. The study will recruit male and female U.S. military Veterans aged 18 and above throughout California and compare change in a comprehensive measure of daytime functioning and change in insomnia, nightmare and overall PTSD symptoms in participants randomized to the active intervention TSC-PTSD vs. participants randomized to a sleep psychoeducation control (SPC) intervention. The widely used and validated World Health Organization Disability Assessment Schedule (WHODAS) will serve as the primary outcome measure. The Insomnia Severity Index (ISI) and the Clinician-Administered PTSD Scale (CAPS) will be used to measure secondary outcomes. Eligible participants will have an insomnia diagnosis, a PTSD diagnosis (or moderate symptoms of PTSD in the absence of a full diagnosis), and clinically significant nightmares based on gold-standard clinician-administered interviews. All participants will complete baseline surveys related to daytime functioning and sleep-related symptoms prior to treatment initiation, and will complete these surveys again in week 5, and at the end of treatment. For additional high-resolution data on sleep patterns, all participants will record sleep-related information, including nightmare occurrence and severity, in the morning and at bedtime using a Veteran-tested and user-friendly sleep diary mobile app. Participants will also complete the clinical interview and self-report surveys at 3-month and 6-month follow-up, to assess the durability of treatment effects. The duration of TSC-PTSD may vary between a minimum of 8 and a maximum of 12 sessions and the psychoeducation control protocol will involve 10 sessions. The hypotheses are: 1) subjects randomized to TSC-PTSD will demonstrate greater improvement in WHODAS score relative to SPC from baseline to post-treatment; 2) subjects randomized to TSC-PTSD will demonstrate greater improvements in insomnia, nightmares and PTSD symptoms as demonstrated by improvements in the ISI, CAPS distressing dreams score, and CAPS total score relative to SPC from baseline to post-treatment; and 3) subjects randomized to TSC-PTSD will demonstrate greater sustained improvement in functional and clinical outcomes at 3-month and 6-month follow-up relative to SPC, and improvements in WHODAS score will be mediated by improvements in ISI, nightmares and TranS-C indicators of sleep health in both study groups. Findings in support of the investigators' hypotheses will provide a vital new tool for advancing rehabilitation in U.S. military Veterans with PTSD.

02

Conditions studied

  • Stress Disorders, Post-Traumatic
  • Sleep Initiation and Maintenance Disorders

Keywords

  • Insomnia
  • Posttraumatic stress disorder
  • Veterans
  • Nightmares
  • Psychotherapy
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • U.S. Military Veteran aged 18 and above engaged in VA primary and/or mental health care
  • Clinician-Administered PTSD Scale (CAPS-5) PTSD diagnosis; or CAPS 5 score >=25 in the absence of full criteria
  • SCID Insomnia Disorder diagnosis, supported by ISI score >=10
  • CAPS-IV nightmare score >=4
  • Sleep-related functional impairment based on a World Health Organization Disability Assessment Schedule (WHODAS) score >=32
  • Willingness to engage in 8-12 sessions of treatment to address their sleep disturbance

Exclusion criteria

Exclusion Criteria:

  • Current cognitive problems, active psychosis or mania, or other mental/cognitive conditions such as moderate to severe neurodegenerative disease that would render the participant unable to connect to videoconferencing platform, engage in remote psychotherapy, or communicate using the required VA secure email platform
  • No access to reliable internet service connected to a computer, iPad or similar device (telephone not adequate)
  • Inability or unwillingness to use a VA-approved videoconferencing platform and VA secure email
  • Current engagement in a sleep-focused psychotherapy, or plan to start a sleep-focused psychotherapy in the next 3 months. Sleep-focused psychotherapies include, but are not limited to, CBT-I, BBT-I, and IRT
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
182 participants (estimated)

Study arms

  • Experimental
    Arm 1: Experimental

    Participants receiving experimental TSC-PTSD treatment.

    Behavioral: TranS-C for PTSD

  • Active comparator
    Arm 2: Active Control

    Participants receiving sleep psychoeducation control.

    Behavioral: Sleep Psychoeducation Control

Interventions

  • BehavioralTranS-C for PTSD

    The Transdiagnostic sleep and circadian intervention (TranS-C), developed by Allison Harvey, Ph.D. and Daniel Buysse, M.D., involves a patient-centered, module-based, flexibly structured approach that tackles numerous sleep disturbances using evidence-based strategies with the goal of improving sleep and related impairments in daytime functioning. It is thus well-suited for tackling sleep disturbances and the associated impairments in social, occupational and overall functioning in Veterans with PTSD. The proposed study is a randomized, controlled clinical trial examining the effectiveness of a modified TranS-C intervention for Veterans with PTSD. The modified approach, TranS-C for PTSD (TSC-PTSD), elevates the importance of nightmare-focused, apnea-focused, and insomnia-focused modules relative to the standard intervention, incorporates an evidence-based relaxation module, and modifies the nightmare and apnea modules based on strategies used for Veterans in the VA healthcare system.

    Also known as: TSC-PTSD

  • BehavioralSleep Psychoeducation Control

    Participants will receive psychoeducation about sleep.

    Also known as: SPC

05

What researchers measure

Primary outcomes

  1. World Health Organization Disability Assessment Schedule (WHODAS)

    The WHODAS is a validated, comprehensive measure of health-related disability.

    Time frame: Week 0, Week 5, Post-Treatment, 3-Month Follow-Up, 6-Month Follow-Up

Secondary outcomes

  1. Insomnia Severity Index (ISI)

    The ISI will be used to measure change in severity of insomnia symptoms.

    Time frame: Week 0, Week 5, Post-Treatment, 3-Month Follow-Up, 6-Month Follow-Up

  2. Clinician-Administered PTSD Scale for DSM-4 Distressing Dream Score (CAPS-4 Nightmare Item)

    The CAPS-IV Nightmare Item will be used to measure change in nightmare symptoms.

    Time frame: Week 0, Week 5, Post-Treatment, 3-Month Follow-Up, 6-Month Follow-Up

  3. Clinician-Administered PTSD Scale for DSM-5 (CAPS-5)

    The CAPS-5 will be used to measure change in overall PTSD symptoms.

    Time frame: Week 0, Post-Treatment, 3-Month Follow-Up, 6-Month Follow-Up

06

Study locations

1 site
  • San Francisco VA Medical Center, San Francisco, CA
    San Francisco, California 94121-1563, United States
    • Emily J Berg · Contact · emily.berg@va.gov · (415) 900-6016
    • Anne Richards, MD MPH · Principal investigator
07

References and documents

Individual participant data

Plan to share: No

08

Registry details

Key details

Study ID
NCT06549049
Lead sponsor
VA Office of Research and Development
Responsible party
Sponsor
First posted
Aug 12, 2024
Start date
Oct 15, 2026 (estimated)
Primary completion
Jan 31, 2029 (estimated)
Completion
Jan 31, 2029 (estimated)
Last update
Sep 29, 2026

Study contacts

Emily J Berg
Contact
emily.berg@va.gov
(415) 900-6016
Anne Richards, MD MPH
principal investigator · San Francisco VA Medical Center, San Francisco, CA

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion